Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
01/16/2017 01/17/2017 01/18/2017 01/19/2017 01/20/2017 Date
48.385(c) 48(c) 49.21(c) 48.75(c) 48.545 Last
66 105 93 411 162 666 84 672 94 014 Volume
-0.99% -0.80% +2.52% -0.93% -0.42% Change
More quotes
Financials (€)
Sales 2016 50,1 M
EBIT 2016 -59,4 M
Net income 2016 -48,7 M
Finance 2016 276 M
Yield 2016 -
Sales 2017 51,4 M
EBIT 2017 -48,0 M
Net income 2017 -38,7 M
Finance 2017 244 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 22,9x
EV / Sales2017 22,9x
Capitalization 1 422 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
01/19 MORPHOSYS : Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients wit..
01/12 MORPHOSYS : Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients wit..
01/12 MORPHOSYS : Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients wit..
01/12 DGAP-NEWS : MorphoSys-Partner startet klinische Phase 2-Studie mit Antikörper Bi..
01/12 DGAP-NEWS : MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Pa..
01/06 NOVARTIS : Dr. Malte Peters to Become New Chief Development Officer of MorphoSys..
01/05 MORPHOSYS : Dr. Malte Peters to Become New Chief Development Officer of MorphoSy..
01/05 MORPHOSYS : Dr. Malte Peters to become new Chief Development Officer of MorphoSy..
01/05 DGAP-NEWS : Dr. Malte Peters wird neuer Chief Development Officer der MorphoSys ..
01/05 DGAP-NEWS : Dr. Malte Peters to become new Chief Development Officer of MorphoSy..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/12MorphoSys AG Partner To Start Phase 2 Trial With Bimagrumab In Obese Patients.. 
01/05Dr. To Become New Chief Development Officer Of MorphoSys AG  
01/05MorphoSys : Dr. Malte Peters to Become New Chief Development Officer of Morph.. 
01/03MorphoSys AG To Present At Upcoming Investor Conferences  
01/03MorphoSys : to Present at Upcoming Investor Conferences  
More tweets
Qtime:26
News from SeekingAlpha
01/12 Novartis to launch mid-stage study of bimagrumab in obese type 2 diabetics
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
2016 Morphosys Ag (MPSYY) Investor Presentation - Slideshow
2016 MorphoSys' (MPSYF) CEO Simon Moroney on Q3 2016 Results - Earnings Call Trans..
2016 MorphoSys AG reports 9M results
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 63,1 €
Spread / Average Target 29%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-1.54%1 518
INCYTE CORPORATION17.21%22 141
QUINTILES IMS HOLDINGS..0.03%18 727
CELLTRION, INC.--.--%10 532
LONZA GROUP AG4.14%9 648
ALKERMES PLC0.90%8 523
More Results